ARCHIVES

FDA Plans to Discuss the Negative Trial of AstraZeneca’s Drug Iressa With the Oncologic Drugs Advisory Committee in March.

This article is from The Cancer Letter archive.

Vol. 31 No. 03 | January 21, 2005

Download PDF Visit The Full Archive

Related Articles

NCCS Networker Volume 1 Issue 2, Summer 1987

June 13, 1987

FDA Approves Generic Oncology Injectable Currently In Shortage

September 27, 2013

Massive New Radiation Research program Costing From $300-$400 Million Over 10 Years Suggested

February 11, 1977

In Brief: Pittsburgh Joins List Of Comprehensive Center Prospect; FDA Schedules Meeting On Cancer Drugs

July 11, 1975

Letters To the Editor: Blumenthal Coverage Called “Destructive”

November 14, 1997

NCI Still Supporting Construction Grants Despite Big Cuts

February 20, 1981